Gland Pharma has received confirmation regarding the dematerialization of its securities for the quarter ended September 30, 2025. The confirmation, received from MUFG Intime India Private Limited, verifies that the securities have been duly processed and listed on the stock exchanges. No requests for either dematerialization or rematerialization were outstanding during this period.
Dematerialization Certificate Received
Gland Pharma announced the receipt of a Confirmation Certificate from MUFG Intime India Private Limited, the Registrar and Share Transfer Agent, regarding the dematerialization of securities. This certificate pertains to the quarter that concluded on September 30, 2025.
Details of Confirmation
The certificate confirms that securities received for dematerialization during Q2 (July-September) 2025 have been duly processed. It also verified that these securities have been listed on the relevant stock exchanges where Gland Pharma’s shares are traded. The company also stated that all security certificates received for dematerialization were verified and subsequently cancelled.
No Outstanding Requests
Gland Pharma clarified that there were no outstanding requests for either dematerialization or rematerialization of securities during the mentioned quarter. This confirms the smooth processing of security-related transactions during the reporting period.
Source: BSE
